20. Adrenoleukodystrophy Clinical trials / Disease details
Clinical trials : 53 / Drugs : 88 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02410239 (ClinicalTrials.gov) | June 2015 | 27/3/2015 | MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) | MT2014-14 Intrathecal Administration of Mesenchymal Stem Cells (IT-MSC) for the Treatment of Advanced Cerebral Adrenoleukodystrophy (cALD) | Cerebral Adrenoleukodystrophy | Biological: Mesenchymal Stem Cells | Masonic Cancer Center, University of Minnesota | NULL | Withdrawn | 4 Years | N/A | All | 0 | Phase 1 | NULL |